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 Acetylcholinesterase inhibitors and gait: a steadying hand?
Cognitive impairment, complex movement disorders, 
and high risk of falls are all inter-related, levodopa-
unresponsive symptoms in patients with advanced 
Parkinson’s disease. Although Parkinson’s disease is 
conventionally viewed as a motor syndrome that results 
from nigrostriatal dopaminergic denervation, there is also 
an intricate interplay between multisystem degeneration 
and neurotransmitter deﬁ cits other than the loss of 
nigrostriatal dopaminergic neurons, especially deﬁ cits in 
the cholinergic system. The degeneration of neurons in 
the nucleus basalis of Meynert (the source of cholinergic 
innervation of the cerebral cortex) is a hallmark of late-
stage parkinsonian dementia and is at least as severe 
as that involved in Alzheimer’s disease.1 Although the 
pathological importance of this degeneration was ﬁ rst 
recognised by Lewy in his report on a series of patients 
with Parkinson’s disease, neuron loss in the nucleus basalis 
of Meynert was not quantiﬁ ed until the 1980s (with 
depletion of up to 80%).2 However, cholinergic denervation 
also occurs in patients with Parkinson’s disease without 
dementia. Therefore, although it might make speciﬁ c 
contributions to the clinical phenotype of Parkinson’s 
disease dementia, the eﬀ ect of denervation seems diverse, 
for instance, central limbic cholinergic denervation 
might be associated with the progressive impairment of 
odour identiﬁ cation.1 Recent evidence also indicates that 
subcortical cholinergic denervation (probably caused by 
degeneration of brainstem pedunculopontine nucleus 
[PPN] neurons) might be associated with dopamine-
refractory gait and balance impairments (including falls) 
in Parkinson’s disease.1 Indeed, the role of cholinergic 
neurons within the mesencephalic locomotor area 
(including the PPN and the cuneiform nucleus) in gait 
has been emphasised by a range of studies in healthy 
people and preclinical studies of lesioned cats and 
primates.3,4 Trials of PPN-directed deep-brain stimulation 
in human beings have mostly targeted freezing of gait, 
and have yielded inconsistent results. 5 In animal models, 
cholinergic–striatal disruption of attentional–motor 
pathways in the basal forebrain is a major cause of falls. 
Additional losses of cholinergic neurons in the PPN can 
worsen posture and gait control. Thus the correlations 
between the various patterns of cholinergic denervation 
and clinical phenotypes in Parkinson’s disease remain 
to be studied. The association between cortical and 
subcortico-mesencephalic cholinergic deﬁ cit in patients 
with Parkinson’s disease without dementia with high-level 
gait disorders (such as freezing of gait), postural instability, 
falls, coupled with dysexecutive syndrome, and apathy 
warrant further research.6
In The Lancet Neurology, Emily Henderson and 
colleagues7 report ﬁ ndings from the randomised ReSPonD 
trial, which studied the eﬀ ects of 32 weeks of high-
dose rivastigmine versus placebo in 130 patients with 
Parkinson’s disease without dementia. Patients had a high 
fall rate (median ﬁ ve falls) in the year before inclusion 
and so were a population at risk of future falls. Patients 
assigned to rivastigmine showed better gait stability at 
32 weeks than did those assigned to placebo. Rivastigmine 
was associated with a 28% (95% CI 11–42; p=0·002) 
greater reduction in adjusted step time variability (used 
to measure gait instability8) during an 18 m walking task 
compared with placebo. However, step time variability in 
a simple dual task (walking while listing words beginning 
with the same letter) was only somewhat improved 
(21% [1–38]; p=0·045), and there was no signiﬁ cant 
diﬀ erence between groups in the high-level cognitive 
dual task (walking while listing words beginning 
with alternating letters; 19% [–9 to 40]; p=0·17). The 
rivastigmine group had signiﬁ cantly fewer falls than did 
the placebo group over the trial period (falls per month 1·4 
[SD 2·47] vs 2·4 [4·40], respectively). However, the drug 
did not have signiﬁ cant eﬀ ects on episodes of freezing of 
gait or assessed neuropsychological outcomes (ie, fear of 
falling, anxiety, and depression).
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patients with Parkinson’s disease with high-level gait 
disorders.9 However, in their open-label pilot study 5 mg 
per day of rivastigmine did not signiﬁ cantly reduce gait 
rhythm disorders, despite improved general mobility 
and lower anxiety being reported by patients. Thus, 
high-dose rivastigmine seems to have a speciﬁ c eﬀ ect on 
postural instability. These results have been long awaited, 
since there are no available pharmacological treatments 
for poor postural stability in Parkinson’s disease.
A high number of adverse events were reported by 
both groups in the ReSPonD.7 Although gastrointestinal 
disorders were probably causally related to rivastigmine, 
many of the adverse events could have been due to the 
high level of comorbidities in the study population. 
Importantly, cardiac adverse events were not more 
frequent in the rivastigmine than in the placebo group 
and the groups did not diﬀ er signiﬁ cantly in Movement 
Disorder Society-Uniﬁ ed Parkinson’s Disease Rating 
Scale (MDS-UPDRS) total score after 32 weeks. Notably, 
no worsening of resting tremor was noted despite 
rivastigmine possibly leading to an imbalance within 
the striatum between lower dopaminergic and higher 
cholinergic neurotransmission, which is associated with 
resting tremor. 
Some questions are yet to be resolved. In particular, 
did rivastigmine have diﬀ erent eﬀ ects on static postural 
stability (assessed by the retropulsion test, item 3.12 of 
the MDS-UPDRS) versus dynamic postural stability (stride-
to-stride variability during gait)? Although Henderson and 
colleagues assessed mood with the Geriatric Depression 
Scale, it would have been useful to investigate apathy 
because an earlier double-blind, placebo-controlled study 
of patients with Parkinson’s disease with pre-dementia 
apathy showed that rivastigmine treatment was associated 
with a lower overall apathy score and caregiver burden and 
greater intellectual curiosity and action initiation.10
Overall, the ﬁ ndings of the ReSPonD trial provide 
valuable arguments in favour of high-dose rivastigmine 
treatment in patients with high-level gait disorders. These 
ﬁ ndings must now be conﬁ rmated in a larger cohort 
of patients with a range of cognitive and behavioural 
proﬁ les, and taking into account the dose eﬀ ect, and the 
long-term risk–beneﬁ t balance.
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Phenytoin in acute optic neuritis: neuroprotective or not? 
Although multiple sclerosis is conventionally 
regarded as an autoimmune, demyelinating disorder 
of the CNS, it is widely accepted that axonal and 
neuronal degeneration, primarily occurring as 
secondary sequelae of inﬂ ammation, are the principal 
pathological substrates underlying disability. Although 
the armamentarium of anti-inﬂ ammatory disease-
modifying therapies for multiple sclerosis continues to 
rapidly expand, neuroprotection and neurorestoration 
are major unmet therapeutic areas. 
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